Besides breast cancer, it has been reported that the CTSK inhibitor could suppress the bone metastasis of advanced prostate cancer, and the CTSK inhibitor also diminished prostate cancer-induced bone lesions [37]. The gene discussed is CTSK; the disease is prostate cancer.